ARTICLE | Clinical News
TiGenix speeds Cx601 timeline
March 7, 2017 11:22 PM UTC
TiGenix N.V. (Euronext:TIG; NASDAQ:TIG) said FDA agreed to a shortened Phase III trial design that would allow the company to submit a BLA for Cx601 one year earlier than originally planned. The study is evaluating the regenerative candidate to treat perianal fistulas in patients with Crohn's disease.
On Tuesday, TiGenix gained €0.03 to €0.75 in Brussels and $0.66 to $15.60 on NASDAQ...
BCIQ Company Profiles